Paper Details

  1. Home
  2. Paper Details

Telavancin: TD 6424, TD-6424.

Author:

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Telavancin is a bactericidal lipoglycopeptide antibacterial in clinical development for skin and soft tissue infections, including MRSA, and nosocomial pneumonia. It has a broad spectrum of activity against Gram-positive pathogens and exhibits a low frequency of spontaneous resistance. Phase III trials are underway in the US.
Paper Details　
Original Abstract of the Article :
Telavancin [TD-6424, ARBELIC] is an injectable, bactericidal lipoglycopeptide antibacterial that is in clinical development with Theravance (formerly Advanced Medicine) in the US. Telavancin, which was discovered by Theravance through the application of multivalent drug design, has a broad spectrum ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2165/00126839-200607060-00008

データ提供：米国国立医学図書館（NLM）

Telavancin: A New Weapon Against Gram-Positive Infections

This research focuses on telavancin, a new lipoglycopeptide antibacterial agent in clinical development for treating various Gram-positive bacterial infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). It's like discovering a new weapon in the battle against infections in a vast desert landscape.

Multi-Pronged Attack

Telavancin's effectiveness stems from its multi-pronged approach to combat bacteria. It inhibits cell wall synthesis and alters bacterial membrane permeability, making it a formidable opponent against bacteria. This makes it difficult for bacteria to develop resistance, much like a fortress with multiple layers of defense.

Promising Results and Future Outlook

The study highlights telavancin's promising efficacy in treating MRSA infections, potentially offering a new solution for this challenging medical problem. It also discusses the ongoing clinical trials and the potential for telavancin to become a valuable tool in the fight against Gram-positive bacterial infections.

Dr.Camel's Conclusion

This research offers a hopeful glimpse into the future of antibacterial therapy, with telavancin potentially becoming a powerful weapon in the fight against resistant bacterial infections. It reminds us that even in the face of seemingly insurmountable challenges, like combating antibiotic resistance, scientists continue to search for new solutions and innovative approaches.
Date :
  1. Date Completed 2007-02-05
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

17073522

DOI: Digital Object Identifier

10.2165/00126839-200607060-00008

Related Literature

Article Analysis
・Effects of telavancin injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.